Sorry, you need to enable JavaScript to visit this website.

CYTARABINE - FOR INTRAVENOUS OR SUBCUTANEOUS USE ONLY (cytarabine injection) Boxed Warning

WARNING

Only physicians experienced in cancer chemotherapy should use Cytarabine Injection.

For induction therapy patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of cytarabine is bone marrow suppression with leukopenia, thrombocytopenia and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration and hepatic dysfunction.

The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. Before making this judgment or beginning treatment, the physician should be familiar with the following text.

What's New

No Current Announcements.

Contact Pfizer Medical

Search

Please enter your search term(s) for CYTARABINE, 500 MG/25 ML MULTI-DOSE VIAL U.S. PHYSICIAN PRESCRIBING INFORMATION